Pro: cardiovascular calcifications are clinically relevant

Area of Science:

• Nephrology
• Cardiology
• Mineral and Bone Disorders

Background:

• Mineral and bone disorders (MBDs) are linked to high cardiovascular (CV) disease rates in chronic kidney disease (CKD).
• Cardiovascular calcification is a key feature of CKD-MBD, prompting debate on clinical screening.
• The modifiability and reversibility of vascular calcification in CKD are critical considerations.

Purpose of the Study:

• To evaluate the role of screening for cardiovascular calcification in CKD patients.
• To discuss the implications of new treatments for CKD-MBD on cardiovascular calcification progression.
• To explore the potential of personalized medicine in managing CV risk in CKD.

Main Methods:

• Review of experimental and clinical evidence on the progression of CV calcification.
• Analysis of current treatment options for CKD-MBD, including calcium-free phosphate binders and calcimimetics.
• Discussion of the limitations of existing hard outcome data.

Main Results:

• Experimental and clinical data suggest that CV calcification progression may be attenuated with new therapies.
• Current hard outcome data are limited and have yielded inconclusive results regarding treatment efficacy.
• The potential for improved outcomes and reduced healthcare costs through targeted screening and therapy is hypothesized.

Conclusions:

• Screening for CV calcification in selected CKD individuals is considered reasonable pending further studies.
• This approach may aid in stratifying CV risk and guiding therapeutic interventions.
• Personalized medicine strategies incorporating CV calcification screening could ultimately enhance patient outcomes and reduce health costs.